Should You Buy Alnylam Pharmaceuticals Before Feb. 12?

Alnylam is expected to report Q4 2025 revenue of roughly $1.16 billion and adjusted EPS of about $1.50 in a likely Feb. 12, 2026 update, driven by continued Amvuttra momentum after Amvuttra sales rose 162% year‑over‑year in Q3 2025 and company guidance forecasts combined Amvuttra/Onpattro sales of $2.5 billion at the midpoint for 2025. Management is likely to confirm that Q4 growth was concentrated in the U.S. and that international Amvuttra contribution remained modest, and to announce pipeline progress including initiation of a Phase 3 nucresiran trial for hATTR‑PN and a Phase 2 mivelsiran Alzheimer's study. Rising Amvuttra royalties are expected to pressure gross margins even as top‑line growth continues, so while the stock looks attractive long term the piece advises a measured entry ahead of the results.

Analysis

Market structure: Alnylam (ALNY) is the clear near-term winner as Amvuttra is driving incremental revenue (Q3 Amvuttra +162% YoY; street Q4 rev est ~$1.16B). Partners receiving royalty escalators are the primary loser — expect company-level gross-margin contraction measured in low- to mid-hundreds of basis points as Amvuttra share increases. US uptake will dominate near term; minimal FX/ex‑US relief until H2 2026 (Germany/Japan). Equity implied vol should compress after the Feb earnings event, while credit risk for ALNY is low-to-moderate given cash flow visibility from drug sales.

Risk assessment: Tail risks include a regulatory setback (label or safety) on Amvuttra or a pivotal trial failure (nucresiran/mivelsiran) — low probability but >30% EBITDA impact if realized. Immediate risk (days): earnings volatility around ~Feb 12, 2026; short-term (weeks–months): ex‑US launch cadence and royalty-driven margin noise; long-term (12–36 months): pipeline readouts and competitive entrants. Hidden dependencies: reimbursement/prior‑auth dynamics and hospital prescriber adoption curves can materially change net patient starts. Key catalysts: Q4 update, Phase‑3 initiation announcement, and first Germany/Japan uptake data in H2 2026.

Trade implications: For event-sensitive capital, avoid buying significant exposure into earnings — prefer defined-risk structures. Tactical approach: small core long (2–3% NAV) or buy a 9–12 month bull-call spread to capture pipeline optionality while capping downside; consider selling short-dated iron condors around earnings only if volatility is rich. Relative play: long ALNY / short IBB (ratio 1:0.5 dollar) to isolate idiosyncratic Amvuttra upside versus biotech beta over 3–12 months.

Contrarian angles: Consensus underprices margin compression from royalties and overprices immediate international upside — market may underreact to non-revenue positives like Phase‑3 starts, which de‑risks longer-term upside. Historical parallel: specialized drug launches often show front-loaded US adoption then long-tail international growth; mispricing opportunity arises if investors overly penalize gross‑margin headwinds while ignoring durable cash flows. Monitor monthly patient-start growth >10% MoM as a buy trigger and royalty step-up disclosures that shift FCF by >5% as a sell/rehab trigger.

Key Decisions for Investors

• Establish a tactical 2–3% NAV long position in ALNY between now and earnings only if prepared for event IV; otherwise defer until 48 hours post‑earnings. If Q4 revenue ≥ $1.16B and Amvuttra YoY growth ≥100% with positive net patient-starts, increase to 4–6% NAV over 2–4 weeks.
• Initiate a defined‑risk options trade: buy a 9–12 month ALNY bull call spread sized to 1–2% NAV (caps upside but limits theta/IV decay) to capture pipeline optionality (target 30–50% upside breakeven).
• Execute a pair trade: long ALNY / short IBB (dollar ratio 1:0.5) sized to 2–4% net exposure to reduce sector beta and capture idiosyncratic Amvuttra upside over 3–12 months.
• If implied volatility for ALNY rises >25% above its 90‑day average into earnings, sell a 30–45 day iron condor (defined risk) for 0.5–1% NAV to collect premium; close 48 hours after results to avoid binary risk.
• Set hard monitoring triggers for position management: reduce exposure by 50% if management revises 2026 guidance down by ≥10%, or if gross margin compresses >200 bps vs prior quarter; add 50% if monthly US patient-start growth accelerates >10% MoM for two consecutive months.